Nevertheless, inhibitors of NF-κB signaling have not had a dramatic impact on general cancer therapy, in part because of the liver toxicity of many NF-κB inhibitors and the rapid development of parallel pathway resistance. This evidence concerns the gene NFKB1 and cancer.